The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo
Open Access
- 1 July 2000
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (1), 63-72
- https://doi.org/10.1172/jci9586
Abstract
We used signal transducer and activator of transcription 4 (STAT4) and STAT6 gene knockout (–/–) mice as recipients of fully mismatched cardiac allografts to study the role of T-cell costimulatory pathways in regulating allogeneic T-helper 1 (Th1) versus Th2 responses in vivo. STAT4–/– mice have impaired Th1 responses, whereas STAT6–/– mice do not generate normal Th2 responses. Cardiac allografts from C57BL/6 mice were transplanted into normal wild-type (WT), STAT4–/–, and STAT6–/– BALB/c recipients. STAT4–/– and STAT6–/– mice rejected their grafts with the same tempo as untreated WT recipients. CD28-B7 blockade by a single injection of CTLA4Ig induced long-term engraftment and donor-specific tolerance in all three groups of recipients. CD154 blockade by a single injection of MR1 was effective in prolonging allograft survival and inducing tolerance in STAT4–/– mice but was only marginally effective in STAT6–/– recipients and WT controls. In addition, a similar protocol of MR1 was ineffective in prolonging graft survival in CD28–/– BALB/c recipients, suggesting that the lack of efficacy seen in WT and STAT6–/– mice is not due to the presence of a functional CD28-B7 pathway. Furthermore, there was a similar differential effect of CD28-B7 versus CD154-CD40 blockade in inhibiting immune responses in animals immunized with ovalbumin and complete Freund’s adjuvant. These novel data indicate that Th1 and Th2 cells are differentially regulated by CD28-B7 versus CD154-CD40 costimulation pathways in vivo and may have potential implications for the development of therapeutic strategies such as T-cell costimulatory blockade in humans.This publication has 66 references indexed in Scilit:
- Lineage-specific Requirement for Signal Transducer and Activator of Transcription (Stat)4 in Interferon γ Production from CD4+ Versus CD8+ T CellsThe Journal of Experimental Medicine, 1999
- CARDIAC ALLOGRAFT TOLERANCETransplantation, 1998
- CHRONIC BLOCKADE OF CD28-B7-MEDIATED T-CELL COSTIMULATION BY CTLA4Ig REDUCES INTIMAL THICKENING IN MHC CLASS I AND II INCOMPATIBLE MOUSE HEART ALLOGRAFTS1,2Transplantation, 1997
- ARE Th2 HELPER T LYMPHOCYTES BENEFICIAL, DELETERIOUS, OR IRRELEVANT IN PROMOTING ALLOGRAFT SURVIVAL?1Transplantation, 1997
- Chimerism and transplantation tolerance: cause and effectImmunology Today, 1996
- Antibody to gp39, the Ligand for CD40 Significantly Inhibits the Humoral Response from Graves' Thyroid Tissues Xenografted into Severe Combined Immunodeficient (SCID) MiceThyroid®, 1996
- THE EFFECTS OF NONDEPLETING CD4 TARGETED THERAPY IN PRESENSITIZED RAT RECIPIENTS OF CARDIAC ALLOGRAFTS1,2Transplantation, 1996
- Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.Journal of Clinical Investigation, 1996
- EXPERIMENTAL GRAFT ARTERIOSCLEROSISTransplantation, 1992
- A TECHNIQUE OF CERVICAL HETEROTOPIC HEART TRANSPLANTATION IN MICETransplantation, 1991